IGF-1 LR3

🔬What Is IGF-1 LR3

IGF-1 LR3 (Insulin-like Growth Factor 1, Long Arginine 3) is an 83-amino acid synthetic analog of native IGF-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension peptide. These modifications dramatically reduce its binding affinity to IGF-binding proteins (IGFBPs), resulting in a significantly longer half-life of approximately 20–30 hours compared to 12–15 minutes for native IGF-1. This extended bioavailability allows sustained activation of the IGF-1 receptor (IGF-1R), promoting potent anabolic signaling through the PI3K/Akt and MAPK/ERK pathways. Research has examined its effects on skeletal muscle hypertrophy, satellite cell proliferation, and glucose metabolism regulation.

📊Clinical Studies & Results

IGF-1 LR3 is an 83-amino acid analogue of insulin-like growth factor-1 with an arginine substitution at position 3 and a 13-amino acid extension, dramatically increasing its half-life and bioactivity:

• ▪The R3 substitution reduces binding to IGF binding proteins (IGFBPs) by over 100-fold, resulting in significantly higher free IGF-1 activity and prolonged biological half-life of ~20-30 hours vs 12-15 minutes for native IGF-1
• ▪Demonstrated potent mitogenic and anti-apoptotic effects on skeletal muscle satellite cells, promoting myoblast proliferation and differentiation in vitro (Ates et al., Exp Cell Res, 2007)
• ▪Promoted hyperplasia (new muscle fiber formation) in addition to hypertrophy, a unique anabolic mechanism not achieved by most growth factors
• ▪Enhanced glucose uptake and glycogen synthesis in muscle tissue through IRS-1/PI3K/Akt signaling pathway independent of insulin receptor activation
• ▪Accelerated wound healing and tissue regeneration with measurable improvements in collagen deposition and tensile strength recovery in preclinical models
• ▪Showed neuroprotective effects through IGF-1R activation in neuronal cells, reducing apoptosis in excitotoxicity and ischemia models

IGF-1 LR3 represents the most bioavailable form of IGF-1, with its dramatically extended half-life and reduced IGFBP binding making it the preferred research tool for studying IGF-1 pathway biology.

🏆Benefits

• 100x Reduced IGFBP Binding – Dramatically higher free IGF-1 activity compared to native IGF-1
• Extended Half-Life – 20-30 hours vs 12-15 minutes for unmodified IGF-1
• Muscle Hyperplasia – Promotes new muscle fiber formation, not just hypertrophy of existing fibers
• Enhanced Glucose Utilization – Improves muscle glucose uptake through insulin-independent Akt signaling
• Tissue Regeneration – Accelerates wound healing and collagen deposition in damaged tissue
• Neuroprotective – Activates IGF-1R to reduce neuronal apoptosis in ischemia and excitotoxicity models

⚠️Possible Side Effects

• ▪Hypoglycemia – IGF-1 LR3 has significant insulin-mimetic effects and can lower blood glucose levels; research protocols typically recommend glucose monitoring and having a carbohydrate source available during administration
• ▪Prolonged use at higher doses has been associated with theoretical risk of internal organ growth (visceromegaly) in published literature, as IGF-1R activation promotes cell proliferation across multiple tissue types
• ▪In subjects with a family history of malignancies, researchers note elevated caution, as sustained IGF-1R stimulation may theoretically promote growth of pre-existing neoplasms
• ▪Joint pain and localized swelling at the injection site have been reported in some research protocols
• ▪Mild water retention may occur due to the anabolic signaling cascade
• ▪Cyclical rather than continuous use patterns are generally preferred in research to mitigate cumulative exposure concerns

🎯Ideal For

• →Anabolic research targeting muscle fiber hyperplasia
• →IGF-1 pathway biology and signaling research
• →Tissue regeneration and wound healing protocols
• →Body composition optimization and lean mass research
• →Neuroprotective research and neuronal survival studies
• →Combining with GH secretagogues (CJC-1295, GHRP-2) for comprehensive anabolic protocols